Zura Bio Limited ZURA
3.72 USD -0.30 (-7.46%)
At closeNov 5, 2026, 6:49 PM EST
3.80 +0.08 +2.15%
After hours · Nov 5, 6:49 PM ET
3.70 Day range 4.01
3.25 52-week range 7.44
- YTD
- -29.01%
- 1 year
- +2.48%
- Market cap
- 358.33M
- EPS (ttm)
- -1.03
- Shares out
- 65.29M
- Forward P/E
- -3.22
- YTD return
- -29.01%
- 1-year return
- +2.48%
- Volume
- 2.65M
- Avg volume
- 2.79M
- Open
- 4.00
- Previous close
- 4.02
- Day's range
- 3.70 – 4.01
- 52-week range
- 3.25 – 7.44
- Beta
- 0.14
- Analysts
- Strong Buy
- Price target
- 14.29 (+284.0%)
- Earnings date
- Aug 13, 2024
MAX -25.40 (-86.34%)
Key statistics
- Enterprise value
- -21.57M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.87M
- Total cash
- 188.22M
- Total debt
- 0
- Return on equity
- -36.85%
- Short % of float
- 9.54%
- 50-day average
- 3.61
- 200-day average
- 3.76
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.29 +284.0% upside
Now 3.72
- Target (low)
- 5.00
- Target (mean)
- 14.29
- Target (high)
- 26.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate 0.00.
Financials — quick view
ZURA Revenue — quarterly 0
ZURA Net income — quarterly -25.82M
ZURA EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.14 | -0.26 | -0.12 | -85.71% |
| Aug 13, 2024 | Jun 1, 2024 | -0.13 | -0.17 | -0.04 | -30.77% |
| Aug 13, 2024 | Jun 1, 2024 | -0.13 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.23 | -0.02 | +0.21 | +91.30% |
| Mar 26, 2024 | Dec 1, 2023 | -0.25 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 8, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 4, 2024 | Leerink Partners | init | — | Outperform |
| Oct 21, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zurabio.com
News
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates 
Zura Bio Q3 EPS $(0.20), Inline 
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates 
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday 
Zura Bio to Participate in the Cantor Global Healthcare Conference 
Contrasting Zura Bio (NASDAQ:ZURA) and Soligenix (NASDAQ:SNGX) 
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22
Your note
Sign in to keep a note on ZURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CABELL CHRISTOPHER H | Officer | Stock Award(Grant) | May 17, 2023 | 162,060 |
| DAVIS KIMBERLY ANN | Officer | Stock Award(Grant) | May 17, 2023 | 492,381 |
| HOWELL MICHAEL | Officer | Stock Award(Grant) | Apr 21, 2024 | 0 |
| MUNSHI AMIT D | Director | Stock Award(Grant) | Apr 21, 2024 | 777,384 |
| NISTALA KIRAN | Officer | Stock Award(Grant) | Apr 21, 2024 | 3,195 |
| PLOOS VAN AMSTEL ARNOUT | Director | Purchase | May 16, 2024 | 100,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 7.44% | 4,860,939 | 11.57M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 5.77% | 3,770,649 | 8.97M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.03% | 3,283,783 | 7.82M | Sep 29, 2024 |
| Great Point Partners LLC | 5.00% | 3,263,672 | 7.77M | Sep 29, 2024 |
| RA Capital Management, L.P. | 4.93% | 3,217,503 | 7.66M | Sep 29, 2024 |
| Braidwell LP | 3.79% | 2,472,806 | 5.89M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.54% | 1,006,940 | 2.40M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.73% | 479,136 | 1.14M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.63% | 408,101 | 971.28K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.31% | 203,558 | 484.47K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.31% | 205,182 | 488.33K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.20% | 132,537 | 315.44K | Aug 30, 2024 |